Excessive Pharmaceutical Marketing Expenditure: Policy Remedies from China
Review of Economics and Statistics · 21.07.2026 · 1-30
DOI: 10.1162/rest.a.1829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Review of Economics and Statistics, online erschienen am 21.07.2026. Verfasst von Chenyuan Liu und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Developing countries face high pharmaceutical prices despite the presence of multiple generic producers. One key reason is excessive spending on sales and marketing by drug firms. This paper examines how centralized drug procurement can curb such marketing efforts and reduce prices, using a policy experiment in China where certain generics are procured through centralized auctions in pilot cities. Winning firms gain large market shares directly without high marketing costs. We find that the centralized auction significantly reduces both sales costs and prices, with winning firms experiencing notable decreases in marketing-related labor demand.
Zitieren
APA
Liu, C., Lu, Y., & Yang, W. (2026). Excessive Pharmaceutical Marketing Expenditure: Policy Remedies from China. Review of Economics and Statistics, 1-30. https://doi.org/10.1162/rest.a.1829
Vancouver
Liu C, Lu Y, Yang W. Excessive Pharmaceutical Marketing Expenditure: Policy Remedies from China. Review of Economics and Statistics. 2026:1-30. doi:10.1162/rest.a.1829
BibTeX
@article{Liu2026,
author = {Liu, Chenyuan and Lu, Yi and Yang, Wanyu},
title = {Excessive Pharmaceutical Marketing Expenditure: Policy Remedies from China},
journal = {Review of Economics and Statistics},
year = {2026},
pages = {1--30},
doi = {10.1162/rest.a.1829}
}
EUVIMED